Evidence map›Paper›PMID 39174782›Full record

ArticleLeukemia2024

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.

Maryam Kazerani, Anetta Marcinek, Nora Philipp, Bettina Brauchle, Jonathan Jonas Taylor, Helena Domínguez Moreno, Andrea Terrasi, Benjamin Tast, Lisa Rohrbacher, Yingshuai Wang and 11 more

Abstract readLetter
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Maryam KazeraniLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.ORCID 0000-0002-5803-4807
Anetta MarcinekLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Nora PhilippLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.ORCID 0000-0002-3918-7795
Bettina BrauchleLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Jonathan Jonas TaylorLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Helena Domínguez MorenoDivision of Molecular Biology, Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.
Andrea TerrasiDivision of Molecular Biology, Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.
Benjamin TastLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Lisa RohrbacherLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Yingshuai WangLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
Maximilian WarmDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Alica-Joana EmhardtDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Giulia MagnoDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-5139-4957
Tobias HeroldDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-9615-9432
Tobias StraubBioinformatics Unit, Biomedical Center, LMU Munich, Martinsried, Germany.
Sebastian TheurichLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.ORCID 0000-0001-5706-8258
Gunnar SchottaDivision of Molecular Biology, Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.ORCID 0000-0003-4940-6135
Roman KischelAmgen Research (Munich) GmbH, Munich, Germany.
Veit L BückleinLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.ORCID 0000-0001-7391-7280
Marion SubkleweLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.ORCID 0000-0001-9154-9469

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 451580403Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2023.004.1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionLeukemia, Myeloid, AcuteT-LymphocytesAntibodies, BispecificBone Marrow CellsFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRecurrenceRemission InductionAntibodies, Bispecific

Identifiers

PMID39174782
PMCPMC11436353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.